Heng Cao,Yonggui Hong,Shouran Zhao,Nengchao Wang,Fuyou Zhou,Xiaodong Xie. Prognostic factors for the survival of 66 cases with extensive stage-small cell lung cancer. Oncol Transl Med, 2016, 2: 12-15. |
Prognostic factors for the survival of 66 cases with extensive stage-small cell lung cancer |
Received:June 21, 2015 Revised:January 28, 2016 |
View Full Text View/Add Comment Download reader |
KeyWord:extensive stage-small cell lung cancer (ES-SCLC); survival rate; prognosis |
Author Name | Affiliation | E-mail | Heng Cao | Department of Oncology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang | caoheng123jun@126.com | Yonggui Hong | Department of Oncology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang | caoheng123jun@126.com | Shouran Zhao | Department of Oncology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang | caoheng123jun@126.com | Nengchao Wang | Department of Oncology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang | caoheng123jun@126.com | Fuyou Zhou | Department of Oncology, The Fourth Affiliated Hospital of Henan University of Science and Technology, Anyang | 395648947@qq.com | Xiaodong Xie | Department of Oncology, The General Hospital of Shenyang Military, Shenyang 110840, China | 67621527@qq.com |
|
Hits: 7060 |
Download times: 8680 |
Abstract: |
Objective: The objective of this retrospective study was to investigate the prognostic factors associated
with survival among patients with extensive stage-small cell lung cancer (ES-SCLC).
Methods: Clinical data from 66 patients with ES-SCLC diagnosed via histopathology or cytology between
July 2005 and July 2009 at Anyang Tumor Hospital (China) were analyzed. Univariate and multivariate
Kaplan-Meier, log-rank, and Cox proportional hazard regression analyses were conducted.
Results: The 12-, 24-, and 36-month survival rates among patients with ES-SCLC were 40.9%, 13.6%,
and 6.1%, respectively. The median survival time (MST) was 10 months. Univariate analyses indicated
that weight loss, efficacy of first-line chemotherapy, total number of chemotherapy cycles, treatment method,
and serum sodium levels significantly influenced survival among patients with ES-SCLC. Multivariate
analyses suggested that the efficacy of first-line chemotherapy, total number of chemotherapy cycles, and
serum sodium levels were independent prognostic factors associated with survival.
Conclusion: The efficacy of first-line chemotherapy, total number of chemotherapy cycles, and serum
sodium levels are important prognostic factors for patients with ES-SCLC. |
Close |
|
|
|